St. Jude Medical (STJ) Receives FDA Approval for New Facility in Puerto Rico
More News related to STJ
- David Moenning’s Daily State of the Markets: 6/26
- St. Jude Medical Applauds MADIT-CRT Trial
- St. Jude Medical (STJ) Announced FDA Approval of its Cool Point Irrigation Pump
- St. Jude Medical Announces FDA Approval of the Cool Point Irrigation Pump
- St. Jude Medical (STJ) Becomes Leading Sponsor of Clinical Trial to Study Atrial Fibrillation At Mayo Clinic
St. Jude Medical, Inc. (NYSE: STJ) today announced U.S. FDA approval of the company's new facility in Arecibo, Puerto Rico, for the manufacturing of pacemakers and cardiac leads.
The 150,000 square-foot facility, located in Arecibo's Santana Industrial Park, will initially be used to produce St Jude Medical pacemakers and cardiac leads for domestic and international markets, and the company plans to begin manufacturing implantable cardioverter defibrillators at the facility late this year. The new plant will expand the company's cardiac rhythm management manufacturing capacity and is expected to create at least 1,250 new jobs within the next three years.
St. Jude Medical, Inc. designs, manufactures, and distributes cardiovascular medical devices and implantable neurostimulation devices worldwide.
Related Categories
FDAStocks Mentioned
-12.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
